Bausch Health Companies Inc (TSE:BHC) – Analysts at Piper Jaffray Companies upped their Q2 2019 earnings estimates for shares of Bausch Health Companies in a report issued on Wednesday, February 20th. Piper Jaffray Companies analyst D. Amsellem now expects that the company will post earnings per share of $1.32 for the quarter, up from their previous forecast of $1.27. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ Q4 2019 earnings at $1.47 EPS and FY2020 earnings at $5.63 EPS.
Separately, BMO Capital Markets lowered their price target on Bausch Health Companies from C$26.00 to C$25.00 in a research report on Thursday.
Shares of Bausch Health Companies stock opened at C$31.20 on Friday. The company has a market capitalization of $11.06 billion and a P/E ratio of -3.34. Bausch Health Companies has a fifty-two week low of C$18.62 and a fifty-two week high of C$36.52. The company has a quick ratio of 0.72, a current ratio of 1.14 and a debt-to-equity ratio of 764.01.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Article: Quick Ratio
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.